Eisai 2012 First Quarter Aricept Sales Down 20%
This article was originally published in PharmAsia News
Eisai announced first quarter results August 1, and domestic sales of the company’s flagship Alzheimer drug Aricept, launched in November 2011 as a generic drug, decreased by 23.9% as prices of the drug decreased by 16%.
You may also be interested in...
Chugai is pursuing further Japanese litigation over generic rivals to its Edirol brand, this time concerning the eldecalcitol ingredient produced by Nissan Chemical.
The European Commission has unexpectedly concluded that CBD should not be considered as a drug opening up the path to a regulated EU market for the cannabinoid as a novel food.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.